The greatest concern of increased anticoagulation use is an increased risk of bleeding in general and of intracranial hemorrhage (ICH) in particular. In studies of patients on oral anticoagulation, ICH was shown to be the most devastating adverse event overall; these patients also had more extensive bleeding and increased mortality compared to patients with spontaneous ICH.5 , 6 While information on bleeding remains limited in COVID-19 patients, one study suggested that many COVID-19 patients with high risk of thrombosis were simultaneously at increased risk for bleeding.7 Although there have been recent publications about ischemic stroke in COVID-19 patients,1 literature regarding ICH in patients with COVID-19 is currently limited.8 , 9 We evaluated the presence of ICH in hospitalized COVID-19 patients and correlated imaging findings with their anticoagulation status.